controlled studies have previously explored the
Second primary tumors after prostate carcinoma
โ Scribed by Fabio Levi; Lalao Randimbison; Van-Cong Te; Georges Erler; Carlo La Vecchia
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 65 KB
- Volume
- 86
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
โฆ Synopsis
Several large datasets have shown a reduced risk of all neoplasms after a diagnosis of prostate carcinoma but an increased incidence rate of urologic carcinoma has been suggested.
๐ SIMILAR VOLUMES
## BACKGROUND. The cyclin D1 gene is amplified and/or overexpressed in several types of human cancer, including cancers of the breast, esophagus, head, and neck. However, the role of cyclin D1 in prostate cancer has not been previously studied in detail. METHODS. Six human prostate cancer cell lin
## BACKGROUND. In the treatment of prostate carcinoma, radiotherapy and surgery are common choices of comparable efficacy; thus a realistic comparison of the potential long term sequelae, such as the risk of second malignancy, may be of relevance to treatment choice. ## METHODS. Data regarding th
Of 984 patients with corpus cancer treated at Roswell Park Memorial Institute (between 1940 and 1960), 116 (11.8%) were found to have second primaries; of these, 47 had breast cancer, 15 skin cancer, 27 other pelvic cancers, 15 abdominal cancer, 3 head and neck cancer, and 3 lymphoma or leukemia. T
## BACKGROUND. The frequency of mutant p53 in bone marrow metastases of patients with carcinoma of the prostate (CaP) and in matched sets of metastatic and primary lesions from the same patients was investigated. The data were examined in relation to prior treatment with androgen ablation (AA) the